Advertisement

Topics

Study of Combination Immunotherapy for the Generation of HER-2/Neu Specific Cytotoxic T Cells

2014-07-23 21:48:12 | BioPortfolio

Summary

This will be a single arm phase I-II single institution clinical trial in patients with HER2 overexpressing Stage IV breast and ovarian cancer who are on maintenance trastuzumab alone after being treated with chemotherapy and trastuzumab or trastuzumab alone to NED or stable disease. Patients will receive a monthly vaccination for 6 months with a HER2 CTL peptide-based vaccine.

Description

Study Population:

Patients with HER2 overexpressing Stage IV breast cancer who are on maintenance trastuzumab alone after being treated with chemotherapy and trastuzumab until there is no evidence of disease (NED) or stable disease. Stage IV HER2 overexpressing ovarian cancer patients who are on maintenance trastuzumab alone or after being treated with chemotherapy and trastuzumab until there is no evidence of disease (NED) or stable disease.

Patients must be HLA-A2.

Rationale:

Data from tumor vaccine studies now indicate there might be survival advantages for patients who have received tumor-antigen specific vaccinations. Our group has demonstrated a potential survival advantage for patients with advanced stage HER2 overexpressing breast cancer immunized with a HER2 peptide based vaccine after being treated to maximal response or complete remission with standard therapy. Recent studies have demonstrated that "sensitization" of HER2 overexpressing tumor cells with trastuzumab, in vitro, will enhance the function of CTL specific for HER2. Theoretically, the mechanism of trastuzumab's enhancement of a HER2 specific CTL response might be the internalization of the HER2 receptor, degradation of the HER2 protein, and increased MHC-peptide presentation with a resultant increase in CD8+ HER2 specific CTL function. Thus, combination of trastuzumab with HER2 peptide based vaccine designed to elicit CTL in the context of HLA-A2 may even further enhance the generation of a HER2 specific CTL response and potentially translate into improved survival for advanced stage breast and ovarian cancer patients when used in the adjuvant setting.

This proposal outlines a clinical trial designed to utilize the potential synergistic effect between trastuzumab and a HER2 CTL generating peptide based vaccine (HER2 CTL vaccine) in order to increase CTL precursor frequencies that target HER2 specific epitopes. Patients will be treated to NED or stable disease with chemotherapy and trastuzumab or trastuzumab alone and while on maintenance trastuzumab receive vaccinations with a HER2 CTL vaccine.

Objectives

Primary:

1. To evaluate the safety of administering a HER2 CTL peptide-based vaccine to Stage IV breast and ovarian cancer patients receiving maintenance trastuzumab.

2. To quantify and characterize antigen specific T cells directed against HER2 in PBMC of patients after vaccination with a HER CTL peptide-based vaccine administered while receiving maintenance trastuzumab.

Secondary:

1. To evaluate overall survival (OS) in Stage IV breast cancer patients who complete a vaccination series with a HER2 CTL peptide-based vaccine while receiving maintenance trastuzumab.

Study Design:

This will be a single arm phase I-II single institution clinical trial in patients with HER2 overexpressing Stage IV breast and ovarian cancer who are on maintenance trastuzumab alone after being treated with chemotherapy and trastuzumab or trastuzumab alone to NED or stable disease. Patients will receive a monthly vaccination for 6 months with a HER2 CTL peptide-based vaccine.

Number of Patients:

Twenty subjects will be enrolled. This will provide statistically adequate numbers of subjects for gathering (1) safety data and (2) immunologic response data.

Outcome Measures

Primary Endpoints:

1. Safety will be assessed using NCI common toxicity criteria.

2. Immune response will be defined by cytokine flow cytometry (CFC). Specifically, a positive immune response will be defined as a post-vaccination HER2 antigen specific CD8 or CD4 precursor frequency measured by CFC of less than 1:20,000. For subjects who have measurable precursors by CFC at baseline, a positive response will be defined as a 2-fold increase in either T cell subset after vaccination.

HLA-A2 MHC tetramer analysis will be used to demonstrate the specificity of the T cells for the HER2 HLA-A2 defined epitopes. IFN-gamma secreting PBMC precursor frequency will also be measured by ELIspot in order to determine the development of lower precursor frequencies not detected by CFC. ELIspot measurements will not define response.

Secondary Endpoints:

1. Overall survival for all patients will be followed. Survival for the Stage IV breast cancer patients will be compared to historical control. This study will not enroll sufficient numbers of subjects to give statistical power to this endpoint. However, a large difference observed between the treatment group and historical control would give additional impetus for a phase II study of efficacy. Although the study will enroll both breast and ovarian cancer patients, from our extensive experience in combined breast and ovarian cancer vaccine studies for HER2, we anticipate approximately 80% of the subjects enrolled will be Stage IV breast cancer patients.

Study Design

Allocation: Non-Randomized, Control: Uncontrolled, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Breast Cancer

Intervention

HER2 CTL vaccine (plus trastuzumab)

Location

University of Washington
Seattle
Washington
United States
98109

Status

Active, not recruiting

Source

University of Washington

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-07-23T21:48:12-0400

Clinical Trials [6438 Associated Clinical Trials listed on BioPortfolio]

Immunotherapy Vaccine and Herceptin in Breast Cancer

The purpose of this trial is to determine if combination immunotherapy with HER2/neu GP2 peptide + GM-CSF vaccine and trastuzumab is safe and immunologically effective in treatment of pati...

Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer

The purpose of this research study is to determine how well pertuzumab and trastuzumab works in treating breast cancer that has spread to the brain. Pertuzumab and trastuzumab are treatmen...

Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast Cancer

RATIONALE: The monoclonal antibody trastuzumab can locate breast cancer cells that have HER2 on their surface and either kill them or deliver tumor-killing substances to them without harmi...

PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer

HER2 gene amplification increases VEGF production in breast cancers; combined inhibition of HER2 and VEGF enhances response in xenograft models. The upregulation of VEGF in HER2-overexpres...

PET Imaging With 89Zr-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness

Our goal is to investigate the use of 89Zr-trastuzumab as a HER2 imaging agent to determine which patients are likely to respond to targeted HER2 agents as single agent therapy. We are pro...

PubMed Articles [15548 Associated PubMed Articles listed on BioPortfolio]

LMO4 mediates trastuzumab resistance in HER2 positive breast cancer cells.

Breast cancer is the leading cause of cancer-related mortality in women worldwide. Trastuzumab (Herceptin) is an effective antibody drug for HER2 positive breast cancer; or acquired trastuzumab resis...

Phase II Study of S-1 plus Trastuzumab for HER2-positive Metastatic Breast Cancer (GBCCSG-01).

Treatment strategies for patients with human epidermal growth factor 2 (HER2)-positive metastatic breast cancer (MBC) have significantly progressed. The use of trastuzumab, a monoclonal antibody targe...

A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients.

Trastuzumab is a standard treatment for HER2-positive (HER2) breast cancer, but some patients are refractory to the therapy. MicroRNAs (miRNAs) have been used to predict therapeutic effects for variou...

Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001-2016).

Patients treated with trastuzumab for HER2-positive metastatic breast cancer (HER2+MBC) are living longer, but there is little information on their outcomes and treatment experience beyond the median ...

A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP.

For human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) with progression on trastuzumab-based therapy, continuing trastuzumab beyond progression and switching to la...

Medical and Biotech [MESH] Definitions

A humanized monoclonal antibody against the ERBB-2 RECEPTOR (HER2). As an ANTINEOPLASTIC AGENT, it is used to treat BREAST CANCER where HER2 is overexpressed.

Abnormal accumulation of lymph in the arm, shoulder and breast area associated with surgical or radiation breast cancer treatments (e.g., MASTECTOMY).

Metastatic breast cancer characterized by EDEMA and ERYTHEMA of the affected breast due to LYMPHATIC METASTASIS and eventual obstruction of LYMPHATIC VESSELS by the cancer cells.

A infiltrating (invasive) breast cancer, relatively uncommon, accounting for only 5%-10% of breast tumors in most series. It is often an area of ill-defined thickening in the breast, in contrast to the dominant lump characteristic of ductal carcinoma. It is typically composed of small cells in a linear arrangement with a tendency to grow around ducts and lobules. There is likelihood of axillary nodal involvement with metastasis to meningeal and serosal surfaces. (DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1205)

A deoxycytidine derivative and fluorouracil PRODRUG that is used as an ANTINEOPLASTIC ANTIMETABOLITE in the treatment of COLON CANCER; BREAST CANCER and GASTRIC CANCER.

More From BioPortfolio on "Study of Combination Immunotherapy for the Generation of HER-2/Neu Specific Cytotoxic T Cells"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Breast Cancer
Track and monitor developments in breast cancer research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on breast cancer and follow companies active in the development of breast cancer tr...


Searches Linking to this Trial